Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT05039736 Withdrawn - Clinical trials for Hepatocellular Carcinoma

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Start date: February 24, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn about the safety and effectiveness of cabozantinib and nivolumab in people with hepatocellular carcinoma (HCC).

NCT ID: NCT05038397 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial

Therasphere
Start date: January 30, 2018
Phase: N/A
Study type: Interventional

A study to evaluate efficacy and safety of TheraSphere and resection combination therapy in patients with single large ((> 5cm, long diameter ) hepatocellular carcinoma :

NCT ID: NCT05038254 Recruiting - Clinical trials for Stage IV Pancreatic Cancer AJCC v8

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emergency room visits and hospitalizations, better quality of life, fewer symptoms, and fewer treatment delays) than patients who receive usual care.

NCT ID: NCT05035108 Recruiting - Hepatoma Resectable Clinical Trials

The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

Start date: November 10, 2020
Phase: Early Phase 1
Study type: Interventional

It is a prospective, non-randomized, single-arm cohort study. A total of 10 patients will be included in this study. Based on standardized treatment, the treatment of bioartificial liver device will be applied 24-48 hours after extensive hepatectomy. In order to evaluate the security and effectiveness of the device, liver function, liver volume, the incidence of liver failure and other results will be analyzed.

NCT ID: NCT05033522 Recruiting - Clinical trials for Hepatocellular Carcinoma

Immunotherapy for Advanced Liver Cancer

ALIVE
Start date: August 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including subjects with macrovascular involvement and/or extrahepatic spread (not eligible for TACE, surgery or locoregional treatment) with Child-Pugh stage A or B liver function. 150 subjects will be randomized 2:1 to AlloStim® immunotherapy vs Physician's Choice of Sorafenib, Lenvatinib or FOLFOX4.

NCT ID: NCT05031949 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-Resectable

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

CCGLC-003
Start date: October 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.

NCT ID: NCT05029973 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Start date: May 10, 2021
Phase: Phase 2
Study type: Interventional

To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.

NCT ID: NCT05027425 Recruiting - Clinical trials for Hepatocellular Carcinoma

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.

NCT ID: NCT05024539 Recruiting - Clinical trials for Hepatocellular Carcinoma

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Start date: June 20, 2021
Phase:
Study type: Observational

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

NCT ID: NCT05022927 Recruiting - Clinical trials for Hepatocellular Carcinoma (HCC)

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.